Upfront Payments in Biotech Deals
How much are biotech companies receiving upfront on average from their collaborators, relative to the clinical phase of the product being licensed? To find out, we took 445 deals since 1989 in which an upfront payment was made and broke out the average upfront license fees and equity payments by clinical phase of the most advanced product licensed in the deal.
You may also be interested in...
Pharma is looking to GAVI to oversee a fair distribution and avoid ‘vaccine nationalism’ – but countries can still sign bilateral deals with companies.
The US agency has released a document explaining what COVID-19 testing supplies may be substituted.
Marketing consultant Buzzback surveyed 800 consumers in March, prior to novel coronavirus shutdowns in the two countries, to identify ingredients that offer opportunities for brands in health care, wellness and skin care.